Clients/1598/00283791.DOCX/11 } EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and between FIRST INTERSTATE BANCSYSTEM, INC. and CASCADE BANCORP _____________________ Dated as of November 17, 2016 75014.000017 EMF_US 62741345v15Version Agreement • November 17th, 2016 • Cascade Bancorp • State commercial banks • New York
AGREEMENT BETWEEN NOTE HOLDERS Dated as of December 28, 2018 by and between UBS AG, by and through its branch office at 1285 Avenue of the Americas, New York, New York, (Initial Note A-1 Holder), and UBS AG, by and through its branch office at 1285...Version Agreement • December 28th, 2018 • UBS Commercial Mortgage Trust 2018-C15 • Asset-backed securities • New York
This AGREEMENT BETWEEN NOTE HOLDERS (this “Agreement”), dated as of December 28, 2018 by and between UBS AG, by and through its branch office at 1285 Avenue of the Americas, New York, New York (“UBS AG, New York Branch” (together with its successors and assigns in interest, as initial owner of Note A-1 described below, in its capacity as the “Initial Note A-1 Holder” and, in its capacity as the initial agent, the “Initial Agent”)) and UBS AG, New York Branch (together with its successors and assigns in interest, as initial owner of Note A-2 described below, in its capacity as the “Initial Note A-2 Holder”); the Initial Note A-1 Holder and the Initial Note A-2 Holder are referred to collectively herein as the “Initial Note Holders”).
ii - 3.26 Bank Secrecy Act, Foreign Corrupt Practices Act and U.S.A. Patriot Act ...........28 ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF FNB ..........................................28 4.1 Corporate Organization ..........Version Agreement • August 7th, 2015 • Metro Bancorp, Inc. • State commercial banks • Pennsylvania
CONTENTSVersion Agreement • July 30th, 2020
ContractVersion Agreement • May 5th, 2020 • California
EX-10.6 9 exhibit106.htm EXHIBIT 10.6 Exhibit 10.6 EXECUTION VERSION AGREEMENT AND CONSENT This AGREEMENT AND CONSENT (this “Agreement”) is effective as of November 7, 2018 by and among Sorrento Therapeutics, Inc., a Delaware corporation (the “Company”), and the holders of warrants to purchase such number of shares of common stock of the Company as is set forth on EXHIBIT A hereto (collectively, the “Warrant Holders”). Capitalized terms used and not otherwise defined herein shall have their respective meanings as set forth in those certain Convertible Promissory Notes in an aggregate principal amount of $37,848,750, dated as of June 13, 2018, issued by the Company (the “Notes”) pursuant to that certain Securities Purchase Agreement dated March 26, 2018, as amended on June 13, 2018, by and among the Company and the purchasers identified on Schedule A thereto (as amended, the “Purchase Agreement”). RECITALS WHEREAS, pursuant to the Purchase Agreement, the Company issued and sold to the W
CONTENTSVersion Agreement • October 14th, 2020
